secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001193125-25-247658
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics discloses $152.8M cash; provides vopimetostat clinical update
--------------------------------------------------------------------------------

- Estimated cash, cash equivalents, and marketable securities of $152.8M as of Sept 30, 2025 (preliminary, unaudited).
- Clinical slide presentation on ongoing Phase 1/2 trial of vopimetostat (TNG462) made available on Oct 23, 2025.
- Cash estimate subject to completion of financial closing procedures and may change materially; auditor has not reviewed.
- No full financial results or specific clinical data included in the disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312525247658/0001193125-25-247658-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312525247658/d88744d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-247658

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer